Latest Breaking News On - Dmitry zamoryakhin - Page 3 : comparemela.com

Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease

ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines

United kingdomUnited statesCity ofMatthew chandler rob patrickMidatech pharma plcviewDmitry zamoryakhinTim metcalfe grahamEdison group us investor relationsStrand hanson limited nominated adviserLondon stock exchangeMidatech pharmaAdvisory limited financialExchange commissionChemoresistant ovarianIntj molHanson limited

Midatech Pharma (MTP) Announces R&D Programme Focused on Leptomeningeal Disease

Midatech Pharma (MTP) Announces R&D Programme Focused on Leptomeningeal Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofUnited statesTim metcalfe grahamMatthew chandler rob patrickDmitry zamoryakhinExchange commissionStrand hanson limited nominated adviserLondon stock exchangeAdvisory limited financialEdison group us investor relationsMidatech pharmaWall streetChemoresistant ovarianIntj molHanson limited

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofDmitry zamoryakhinLondon stock exchangeFinancial conduct authorityColumbia universityExchange commissionAmerican medical associationEuropean union withdrawalMidatech pharmaPlanned dose escalationData safety monitoring boardTemozolomide aloneRandomized clinicalAmerican medical

Midatech Pharma Phase I study of MTX-110 in rGB will continue with a planned dose escalation

Midatech Pharma Phase I study of MTX-110 in rGB will continue with a planned dose escalation

United statesDmitry zamoryakhinMidatech pharmaAmerican medical associationColumbia universityData safety monitoringTemozolomide aloneRandomized clinicalAmerican medical

Midatech Pharma PLC - First Patient Enrolled in Phase 1 Study of MTX-110

Midatech Pharma PLC - First Patient Enrolled in Phase 1 Study of MTX-110
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofSan franciscoDmitry zamoryakhinYannick desjardinsUniversity of californiaLondon stock exchangeFinancial conduct authorityColumbia universityExchange commissionAmerican medical associationUniversity of texasDuke universityMidatech pharmaFirst patient enrolled